Abstract Library

#2876 Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)

Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dasari A, Paulson S, Sung M, Tucci C, Kauh J,

Keywords: Neuroendocrine Tumors, Pancreatic, Surufatinib,

#2871 Increase of Ki-67 Index over Time and Influence on All-Cause Mortality in Patients with Neuroendocrine Neoplasms (NEN)

Introduction: Increase of Ki-67 index in NEN over time in relation to progression and a potential influence on prognosis is scarcely studied.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Holmager P

Authors: Holmager P, Langer S, Federspiel B, Willemoe G, Garbyal R,

Keywords: Ki-67 index, Prognosis, Mortality,

#2217 Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)

Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Carmona-Bayonas A, Fernandez del Valle A, Solis M, Matos I, Garcia-Carbonero R,

Keywords: CHOI criteria, pancreatic neuroendocrine tumor, RECIST, response, survival,

#2197 Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors

Introduction: Reliable biomarkers represent a crucial unmet need in the management of neuroendocrine tumors. Tumor necrosis has been suggested to have a prognostic value in selected solid tumors but is not included in established WHO NET Grading Systems. However, little is known regarding the influence of tumor necrosis on tumor progression and prognosis in patients with liver metastasis from neuroendocrine tumors.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Atanasov G

Authors: Atanasov G, Tsvetkova I, Strücker B, Andreou A, Bahra M,

Keywords: net, liver metastases, biomarker, tumor necrosis,

#2142 Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Introduction: Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting delta-like protein 3 (DLL3), an atypical Notch receptor family ligand expressed in high-grade neuroendocrine carcinomas (NECs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Mansfield A

Authors: Mansfield A, Aggarwal R, Beltran H, Farago A, Hann C,

Keywords: Rovalpituzumab tesirine, DLL3, neuroendocrine tumors, antibody-drug conjugate,